The phrase innovasis lawsuit has become increasingly associated with several different legal disputes involving Innovasis, a Utah-based medical device company specializing in spinal implants and related technologies. The company has faced litigation involving alleged improper payments to physicians, employment and business disputes, intellectual-property issues, and patent infringement claims. Because these matters involve different courts, defendants, allegations, and outcomes, treating them as one single lawsuit can create a misleading picture.
The most widely discussed matter is the federal government’s 2024 resolution with Innovasis and two senior executives. According to the U.S. Department of Justice, Innovasis, Brent Felix, and Garth Felix agreed to pay $12 million to resolve allegations that improper remuneration was provided to physicians to encourage the use of Innovasis spinal devices on Medicare patients. The government described payments and benefits involving consulting arrangements, intellectual-property transactions, registry payments, equity interests, travel, meals, and other benefits. The settlement resolved allegations rather than representing a judicial finding after a trial.
At the same time, Innovasis has been involved in separate private litigation. One important case was Innovasis v. Michael Francis English and Curiteva, Inc., filed in the U.S. District Court for the District of Utah in April 2023. That dispute involved allegations concerning former employee Michael English, competition with Curiteva, confidential information, business activities, and contractual obligations. Several procedural rulings followed, including a December 2023 dismissal of an amended complaint against English and additional discovery-related orders in 2024.
Another separate proceeding involved RSB Spine, which sued Innovasis in April 2024 over alleged patent infringement involving spinal implant technology. Public case information indicates that the matter was later closed.
More recently, a new case was filed in June 2026 under the caption Innovasis Inc. et al. v. English et al., naming Innovasis and Brent A. Felix as plaintiffs and Michael Francis English and Ricardo Fontg as defendants. The federal docket identifies the action as a contract dispute and assigns it case number 2:2026cv00511 in the District of Utah. An amended complaint was filed on June 22, 2026.
Understanding the innovasis lawsuit therefore requires looking at these proceedings separately.
Innovasis Lawsuit: A Quick Overview
| Category | Key information |
|---|---|
| Company | Innovasis, Inc. |
| Industry | Medical devices and spinal implants |
| Principal location | Utah |
| Major federal settlement | $12 million announced in May 2024 |
| Government allegations | Improper payments and inducements involving physicians |
| Relevant statutes | False Claims Act and Anti-Kickback Statute |
| Whistleblower | Robert Richardson, a former Innovasis regional sales director |
| Whistleblower recovery | Approximately $2.2 million |
| Major private litigation | Innovasis v. English and Curiteva |
| Patent dispute | RSB Spine v. Innovasis |
| Newer 2026 litigation | Innovasis and Brent A. Felix v. Michael English and Ricardo Fontg |
| 2026 case number | 2:2026cv00511 |
| 2026 case type | Contract dispute |
| Important distinction | Different Innovasis cases involve different claims and parties |
The table is important because online references to an “Innovasis lawsuit” can otherwise combine several unrelated proceedings.
What Is Innovasis?
Innovasis is a medical device manufacturer associated with spinal surgery and spinal implant products. Court records in the company’s litigation describe it as being involved in the research, development, manufacturing, and marketing of spinal implant devices and related products.
The company operates in a highly specialized part of the medical technology industry. Spinal implants can be used in procedures designed to stabilize the spine, promote fusion, address deformities, treat trauma, or manage other spinal conditions.
Medical-device companies operate within a particularly regulated environment because commercial relationships can overlap with clinical decision-making. Physicians may influence which devices are selected for procedures, while hospitals, insurers, government healthcare programs, and patients can bear the financial consequences.
That regulatory environment is central to understanding the most prominent innovasis lawsuit.
Why the Innovasis Lawsuit Became a Major Legal Story
The 2024 federal settlement attracted significant attention because it involved allegations under two important federal healthcare laws: the False Claims Act and the Anti-Kickback Statute.
The Justice Department announced on May 29, 2024, that Innovasis and executives Brent Felix and Garth Felix had agreed to pay a combined $12 million to resolve allegations that they violated the False Claims Act by providing kickbacks to spine surgeons to induce the use of Innovasis products.
The government said the alleged conduct occurred between January 1, 2014, and December 31, 2022.
According to the DOJ, the alleged improper remuneration involved 17 orthopedic surgeons and neurosurgeons.
The government described several categories of alleged benefits, including consulting fees, intellectual-property acquisition and licensing payments, registry payments, performance shares, luxury travel, dinners, and holiday events.
These allegations were serious because the federal Anti-Kickback Statute generally prohibits certain forms of remuneration intended to induce or reward referrals or purchases involving federally funded healthcare programs.
However, an important legal distinction must be maintained: a settlement resolving allegations is not the same thing as a verdict following a trial. The Justice Department described the matter as a resolution of allegations. The settlement allowed the government to resolve its claims without a judicial determination that every allegation had been proven at trial.
The $12 Million Innovasis Settlement
The financial centerpiece of the most prominent innovasis lawsuit was the $12 million settlement announced in 2024.
The DOJ stated that Innovasis, Brent Felix, and Garth Felix agreed to pay the combined amount to resolve the allegations.
The settlement concerned alleged conduct over approximately nine years.
According to the government’s account, the alleged remuneration was not limited to traditional cash payments. Instead, it allegedly appeared in several forms.
Consulting Fees
The DOJ alleged that some physicians received consulting payments at rates substantially above fair-market value.
The government also alleged that in some circumstances physicians were paid for consulting work that was never performed.
Consulting arrangements can be legitimate in the medical-device industry. Companies may legitimately engage physicians to provide product feedback, clinical expertise, educational input, or research assistance. The legal concern arises when compensation is allegedly structured not for legitimate services but to influence purchasing or referral decisions involving federally reimbursed healthcare.
Intellectual-Property Payments
Another category identified by the DOJ involved payments connected to intellectual property.
The government alleged that Innovasis acquired or licensed purported intellectual property from physicians at amounts exceeding fair market value.
The DOJ further alleged that some of the intellectual property had not been independently valued before purchase and was not subsequently used for meaningful product development.
Again, these statements represent the government’s allegations that were resolved through settlement.
Registry Payments
The government also identified registry payments among the forms of remuneration at issue.
Medical registries can serve legitimate scientific and clinical purposes. They can collect information about patients, procedures, outcomes, device performance, and other clinical factors.
The legal significance depends on the purpose, structure, amount, recipients, and surrounding circumstances of the arrangement.
Equity Interests
The DOJ also referred to performance shares in Innovasis as part of the alleged remuneration.
Equity arrangements can create complex compliance considerations in healthcare because an ownership interest may potentially provide an economic incentive connected to business generated through physicians.
Travel and Hospitality
The government’s allegations also included travel to a luxury ski resort, lavish dinners, and holiday parties involving surgeons, their office staff, and family members.
The Justice Department specifically highlighted these benefits when explaining the settlement.
The inclusion of hospitality in the government’s account demonstrates why medical-device compliance programs often pay close attention to entertainment, travel, meals, and other non-cash benefits.
The Whistleblower Behind the Federal Case
The federal settlement also involved a whistleblower proceeding.
The Justice Department stated that Robert Richardson, a former regional sales director for Innovasis, brought claims under the qui tam provisions of the False Claims Act.
Under the qui tam framework, a private individual may bring certain claims on behalf of the United States and may receive a portion of a recovery if the case produces a qualifying recovery.
The DOJ stated that Richardson would receive approximately $2.2 million as his share of the recovery. The underlying matter was identified as United States ex rel. Richardson v. Innovasis Inc., et al., No. 3:19-CV-02440-X in the Northern District of Texas.
This element is important when discussing the innovasis lawsuit because the federal settlement did not simply emerge as an ordinary government enforcement action. It also incorporated a whistleblower case.
What the Federal Settlement Did Not Establish
One of the most important points for readers researching the innovasis lawsuit is the difference between allegations and adjudicated facts.
A settlement can resolve substantial legal exposure without requiring a court to conduct a full trial on every disputed allegation.
The DOJ announcement uses language describing what the government alleged. It does not describe a jury verdict finding every alleged act proven beyond dispute.
Therefore, responsible reporting should use terms such as “alleged,” “according to the DOJ,” and “the settlement resolved allegations” when describing disputed conduct.
This distinction matters particularly in healthcare litigation, where legal, regulatory, financial, and reputational consequences can be substantial.
The Innovasis v. English and Curiteva Litigation
The federal settlement is not the only significant innovasis lawsuit.
In April 2023, Innovasis filed a separate lawsuit in the U.S. District Court for the District of Utah against Michael Francis English and Curiteva, Inc. The case was assigned number 2:23-cv-00228. The docket identifies the matter as a contract-related diversity case.
English had previously worked for Innovasis from February 2014 until May 2019 and later worked for Curiteva, according to a 2024 federal court order. Curiteva was described as a competitor of Innovasis.
This created a fundamentally different legal context from the federal healthcare settlement.
Rather than focusing primarily on physician payments and federal healthcare reimbursement, the Innovasis- English litigation concerned business competition, employment-related obligations, and disputes surrounding the movement of personnel and technology.
Allegations Concerning Michael English
A December 2023 federal order provides details about the allegations made by Innovasis.
According to the allegations summarized by the court, Innovasis claimed that English had engaged in various activities during and after his employment that conflicted with his obligations to the company.
Among other things, Innovasis alleged that English had helped establish and develop Curiteva, solicited Innovasis employees, used Innovasis resources for outside activities, and engaged in other conduct that Innovasis considered improper.
The complaint also contained allegations involving a company called Core Medical LLC and alleged financial activities connected to Innovasis.
These should be understood as allegations made in litigation rather than findings that automatically establish the truth of each accusation.
The Severance and Whistleblower Allegations
The December 2023 court record also discussed an unusual element of the dispute.
According to the allegations summarized by the court, English sought a severance package of approximately $2 million after announcing his resignation. The allegations stated that he threatened to bring a qui tam action if the requested severance was not provided.
Innovasis allegedly believed English was the whistleblower behind a separate action against the company.
The court record states that a whistleblower case was filed in 2019 and that Innovasis later discovered English was not the whistleblower. Innovasis then filed its lawsuit in April 2023.
This sequence is particularly relevant to readers searching for the innovasis lawsuit because it illustrates how employment disputes, whistleblower proceedings, and competitive business relationships can intersect without necessarily being the same case.
December 2023 Court Ruling
In December 2023, the District Court for the District of Utah granted Michael English’s motion to dismiss Innovasis’s first amended complaint.
The court’s decision is a significant procedural development, but it should not be interpreted as a broad finding that every factual allegation involving Innovasis or English was true or false.
A motion to dismiss generally tests whether the complaint adequately states legally cognizable claims under the applicable procedural standard. It does not ordinarily function as a full trial of disputed evidence.
The court’s December 13, 2023 decision therefore needs to be read within that procedural framework.
Discovery Battles in 2024
The Innovasis litigation continued to generate procedural orders in 2024.
In July 2024, the court addressed competing motions concerning discovery and the deposition of Innovasis president and chairman Brent Felix.
Curiteva sought to compel Felix’s deposition, while Innovasis sought protection and limitations concerning the proposed deposition topics.
The court denied Innovasis’s request for a protective order and granted Curiteva’s request to compel the Rule 30(b)(6) deposition, although the deposition was to be delayed until certain discovery obligations were addressed.
The same month, another order partially granted Innovasis’s motions to compel discovery from Curiteva.
These rulings demonstrate that litigation can continue through extensive discovery even when earlier motions have already altered the scope of the claims.
The Personal-Jurisdiction Issue
Curiteva also challenged whether the Utah court had personal jurisdiction over it.
The court denied Curiteva’s motion to dismiss without prejudice and allowed jurisdictional discovery to proceed.
The dispute required the parties to explore Curiteva’s contacts with Utah and whether those contacts were legally sufficient to support jurisdiction.
A later August 2024 order addressed Curiteva’s objections to third-party subpoenas and protective measures. The court granted Curiteva’s motion in part and limited certain discovery.
This part of the innovasis lawsuit illustrates an important principle in civil litigation: before a court reaches the substance of a dispute, parties can litigate whether the court has authority to hear the claims against a particular defendant.
The RSB Spine Patent Lawsuit
A separate innovasis lawsuit involved RSB Spine.
On April 10, 2024, RSB Spine filed a patent-infringement case against Innovasis in the U.S. District Court for the District of Utah. The case was numbered 2:24-cv-00264.
RSB alleged that Innovasis infringed U.S. Patent No. 9,713,537.
The dispute concerned spinal implant technology and specifically involved Innovasis’s Ax Stand-Alone ALIF System.
A complaint described the case as an action for patent infringement arising under federal patent law. It alleged that Innovasis manufactured and distributed spinal therapy products, including anterior lumbar interbody fusion devices.
What RSB Spine Alleged
According to reporting at the time, RSB Spine alleged that Innovasis knowingly infringed its patent.
The complaint reportedly claimed that RSB had previously sent Innovasis notices concerning alleged infringement, including correspondence beginning in 2018 and additional communications in later years.
RSB sought damages and requested a jury trial.
These were allegations in a patent case, not an established finding of infringement.
What Happened to the RSB Spine Case?
The RSB Spine litigation did not develop into a publicly reported full trial verdict.
Public case information indicates that the matter was later closed, and secondary case-tracking information reports that the plaintiff voluntarily dismissed the action with prejudice in October 2024.
A dismissal with prejudice generally means the same claims cannot simply be brought again in the same form.
However, the public record available through ordinary case summaries does not necessarily disclose every term of a private resolution. Therefore, readers should be cautious about assuming that a dismissal with prejudice automatically proves that one side admitted liability, prevailed on the merits, or entered a particular type of settlement.
The New 2026 Innovasis Lawsuit
The term innovasis lawsuit has another important meaning in 2026.
On June 1, 2026, Innovasis and Brent A. Felix filed a new federal action against Michael Francis English and Ricardo Fontg in the District of Utah.
The case number is 2:2026cv00511.
The docket categorizes the action as a contract dispute under diversity jurisdiction. Innovasis and Felix are listed as plaintiffs, while English and Fontg are listed as defendants.
An amended complaint was filed on June 22, 2026.
The initial filing included a settlement agreement as an exhibit, according to the publicly available docket summary.
Because the 2026 case is distinct from the 2023 litigation, it should not automatically be treated as a continuation of every claim in the earlier case.
Why the 2026 Case Matters
The 2026 filing demonstrates that Innovasis’s legal disputes did not end with the 2024 federal settlement.
It also shows why searches for innovasis lawsuit can produce multiple results.
A person searching only the company’s name may encounter:
- the federal healthcare settlement;
- the Innovasis v. English and Curiteva litigation;
- the RSB Spine patent dispute;
- the 2026 Innovasis and Brent Felix action involving English and Fontg;
- older litigation involving Innovasis and other companies.
These cases involve different causes of action and different legal questions.
Innovasis Lawsuit and Healthcare Compliance
The 2024 settlement highlights broader compliance issues relevant to medical-device companies.
A company can legitimately compensate physicians for bona fide consulting services. It can also legitimately conduct research, develop intellectual property, organize educational programs, and provide certain forms of professional support.
The legal risk arises when financial relationships are allegedly designed to influence clinical purchasing decisions or generate federally reimbursed business improperly.
The Innovasis settlement illustrates why healthcare companies often need detailed policies covering:
- Physician consulting agreements
- Fair-market-value assessments
- Intellectual-property transactions
- Travel and lodging
- Meals and entertainment
- Equity arrangements
- Clinical registries
- Documentation of services
- Compliance training
- Executive oversight
The DOJ specifically emphasized the importance of preventing payments intended to influence physician device-selection decisions.
Why Fair Market Value Matters
Fair-market-value analysis is an important concept in healthcare compliance.
Suppose a physician provides legitimate consulting services worth a particular amount. Paying the physician a commercially reasonable amount for documented services can be fundamentally different from paying substantially more than the value of the work as an inducement to select a particular medical product.
The allegations in the federal innovasis lawsuit specifically referenced consulting arrangements that the government characterized as exceeding fair market value.
The DOJ also alleged that some payments were made for services that were not performed.
These allegations explain why companies in regulated industries often require contracts, written scopes of work, invoices, documentation, time records, compliance review, and independent valuation.
The Role of Corporate Leadership
The DOJ’s announcement also placed attention on senior management.
According to the government, Brent Felix and his brother Garth Felix held leadership positions and allegedly controlled or directed Innovasis operations, strategic decisions, and arrangements with physicians who received the alleged remuneration.
Corporate compliance therefore cannot necessarily be delegated entirely to a compliance department.
Board oversight, executive accountability, internal controls, documentation, and independent review can all become important when a business operates in a highly regulated healthcare market.
Does the Innovasis Lawsuit Mean Innovasis Was Found Guilty?
No single answer can accurately describe all of the company’s litigation because there are multiple cases.
The 2024 federal matter was resolved through a $12 million settlement of allegations.
The DOJ did not announce a criminal conviction of Innovasis in that settlement announcement. The case was a civil False Claims Act and Anti-Kickback Statute matter.
The 2023 Innovasis v. English and Curiteva case involved private civil litigation and procedural rulings.
The RSB Spine matter involved patent infringement allegations and was later closed.
The 2026 case is a separate contract-related lawsuit that, based on the public docket information available for this article, remained a litigation matter rather than a final adjudication.
Therefore, saying simply that “Innovasis lost a lawsuit” would collapse several legally distinct proceedings into one inaccurate statement.
What Readers Should Know About the $12 Million Figure
The $12 million figure is frequently the first number encountered when researching innovasis lawsuit.
It is important to understand what that amount represents.
According to the DOJ, it was the total amount Innovasis and the two named executives agreed to pay to resolve the federal government’s allegations.
It does not mean that a jury awarded $12 million after trial.
It also does not mean that $12 million represented damages in the separate Curiteva litigation or the RSB Spine patent case.
Each case had its own legal theory, parties, procedural history, and potential remedies.
The Difference Between a Settlement and a Judgment
A settlement is an agreement resolving a dispute.
A judgment is a formal determination entered by a court.
These concepts can have very different meanings.
A settlement may occur because parties want to reduce litigation costs, eliminate uncertainty, avoid prolonged discovery, resolve regulatory exposure, or achieve another negotiated outcome.
A judgment generally follows judicial determination of a dispute or a procedural disposition by the court.
In the federal Innovasis healthcare matter, the DOJ described the resolution as a settlement of allegations.
That wording should be retained in any accurate discussion of the case.
Why the Whistleblower Component Is Significant
The False Claims Act contains mechanisms that can allow private whistleblowers to bring certain claims on behalf of the government.
This creates an important enforcement pathway in areas where government agencies may not immediately have access to internal company information.
Former employees can sometimes possess detailed knowledge of contracts, payment arrangements, sales practices, communications, or compliance concerns.
In the Innovasis matter, the DOJ identified Robert Richardson as the former regional sales director whose qui tam claims were resolved as part of the settlement. The government stated that Richardson would receive approximately $2.2 million.
Innovasis Lawsuit Timeline
2014–2022: Period Identified in the Federal Allegations
The DOJ said the alleged improper remuneration occurred between January 1, 2014, and December 31, 2022.
2019: Whistleblower Litigation
The government identified a 2019 qui tam action brought by former Innovasis regional sales director Robert Richardson.
2023: Innovasis Sues English and Curiteva
Innovasis filed its lawsuit against Michael English and Curiteva on April 10, 2023.
December 2023: Motion to Dismiss Granted
The District of Utah granted English’s motion to dismiss Innovasis’s first amended complaint.
2024: Discovery Litigation
The court issued several orders addressing depositions, jurisdictional discovery, motions to compel, and protective orders.
April 2024: RSB Spine Patent Case
RSB Spine sued Innovasis over alleged infringement of a spinal-implant patent.
May 2024: $12 Million Federal Settlement Announced
The DOJ announced the settlement involving Innovasis, Brent Felix, and Garth Felix.
October 2024: RSB Spine Case Closed
Public case-tracking information indicates the RSB Spine litigation was later dismissed with prejudice.
June 2026: New Innovasis Litigation
Innovasis and Brent A. Felix filed a new action against Michael English and Ricardo Fontg. An amended complaint followed on June 22, 2026.
How to Interpret Online Claims About the Innovasis Lawsuit
Internet searches can make complicated litigation appear much simpler than it really is.
A headline may say “Innovasis sued,” while another says “Innovasis settles lawsuit,” and another discusses a former employee or patent dispute.
Those statements can all refer to different events.
A reliable approach is to identify five things:
1. The Case Name
Check the exact caption.
2. The Case Number
Federal cases receive unique docket numbers.
3. The Court
A case in the District of Utah is not necessarily related to another matter involving Innovasis in a different court.
4. The Cause of Action
Contract disputes, patent cases, and False Claims Act cases involve different legal standards.
5. The Procedural Outcome
A dismissal, settlement, judgment, denial of a motion, and discovery order have very different meanings.
This framework is particularly useful when researching innovasis lawsuit because multiple proceedings involve overlapping people and corporate relationships.
Is the Innovasis Lawsuit Still Ongoing?
There is no single “Innovasis lawsuit” with one universal status.
The 2024 federal healthcare matter was resolved through the announced $12 million settlement.
The RSB Spine patent case was later closed.
The older Innovasis v. English and Curiteva litigation generated multiple court orders in 2024.
A separate case involving Innovasis, Brent Felix, Michael English, and Ricardo Fontg was filed in June 2026 and received an amended complaint later that month. The public docket information available for this article identifies it as a contract case.
Consequently, anyone asking whether the innovasis lawsuit is “over” should first specify which case they mean.
Frequently Asked Questions
What is the Innovasis lawsuit about?
The phrase can refer to several different legal proceedings involving Innovasis. The most prominent was the federal healthcare case resolved in 2024 through a $12 million settlement involving allegations of improper payments to physicians. Other cases have involved former employees, business competition, and patent infringement.
Did Innovasis pay $12 million?
Yes. According to the U.S. Department of Justice, Innovasis and executives Brent Felix and Garth Felix agreed to pay a combined $12 million to resolve federal allegations involving improper remuneration to physicians.
Was Innovasis convicted of a crime?
The 2024 DOJ announcement described a civil settlement resolving allegations under the False Claims Act and Anti-Kickback Statute. It did not announce a criminal conviction of Innovasis.
Who was the whistleblower in the Innovasis case?
The DOJ identified Robert Richardson, a former Innovasis regional sales director, as the whistleblower whose qui tam claims were resolved as part of the federal settlement. The government said he would receive approximately $2.2 million.
What did the government allege Innovasis did?
According to the DOJ, Innovasis allegedly provided improper remuneration to 17 orthopedic surgeons and neurosurgeons to induce the use of Innovasis spinal devices for Medicare beneficiaries. The alleged remuneration included consulting fees, intellectual-property payments, registry payments, performance shares, travel, meals, and other benefits.
Was the $12 million settlement a court judgment?
No. It was a settlement resolving government allegations. A settlement should not automatically be described as a trial verdict or jury finding.
What was the Innovasis v. English case?
It was a separate civil lawsuit filed by Innovasis in the District of Utah in 2023 against Michael Francis English and Curiteva. It involved allegations related to employment obligations, competition, business activities, and related disputes.
What happened in the English case?
The court granted English’s motion to dismiss Innovasis’s first amended complaint in December 2023. The litigation also generated several discovery-related orders during 2024.
Did Innovasis face a patent lawsuit?
Yes. RSB Spine filed a patent-infringement lawsuit against Innovasis in April 2024 involving a spinal implant patent and the Innovasis Ax Stand-Alone ALIF System.
What happened to the RSB Spine case?
Public case information indicates that the case was later closed, with secondary case-tracking information reporting a voluntary dismissal with prejudice in October 2024.
Is there another Innovasis lawsuit in 2026?
Yes. A federal case filed June 1, 2026, lists Innovasis and Brent A. Felix as plaintiffs and Michael Francis English and Ricardo Fontg as defendants. The docket identifies the matter as a contract dispute and lists case number 2:2026cv00511. An amended complaint was filed June 22, 2026.
Does every Innovasis lawsuit involve the same allegations?
No. The cases concern different legal issues. The federal settlement involved healthcare-related allegations, while the English litigation involved business and employment disputes, and the RSB Spine matter concerned patent infringement.
Why is the phrase “Innovasis lawsuit” confusing?
Because several distinct proceedings have involved the company. Search results can place the federal settlement, employee litigation, patent litigation, and newer contract disputes next to one another even though they are legally separate.
Can a settlement be treated as proof that every allegation was true?
No. A settlement resolves a dispute but does not necessarily constitute a judicial finding that every disputed allegation was proven. Accurate reporting should distinguish allegations, admissions, findings, and negotiated resolutions.
What should readers check before discussing the Innovasis lawsuit?
Readers should check the case caption, docket number, court, filing date, claims, parties, and procedural outcome. Those details help distinguish one Innovasis proceeding from another.
A Broader View of the Innovasis Legal History
The Innovasis legal record illustrates how one medical-device company can become involved in several very different forms of litigation at different points in time.
The 2024 federal settlement is the most significant matter from a healthcare-compliance perspective. The Justice Department’s allegations concerned relationships between a medical-device manufacturer and physicians, with the government asserting that improper remuneration was connected to the use of Innovasis products for Medicare beneficiaries. The $12 million settlement brought that federal dispute to a negotiated resolution.
The English and Curiteva litigation belongs to another category. It demonstrates the complexity that can arise when experienced employees move between competing medical-device companies. Questions concerning contractual restrictions, confidential information, business opportunities, personnel recruitment, jurisdiction, and discovery can produce extensive civil litigation.
The RSB Spine case adds an intellectual-property dimension. Medical-device manufacturers often compete not only through sales and clinical relationships but also through engineering, manufacturing processes, implant designs, patents, and proprietary technologies.
Finally, the 2026 case involving Innovasis, Brent Felix, Michael English, and Ricardo Fontg shows that legal disputes connected with the company continued to develop after the earlier cases. The public docket confirms the existence of that case and the filing of an amended complaint, but the docket information alone should not be used to predict its eventual outcome.
For anyone researching innovasis lawsuit, the most reliable picture is therefore not a single dramatic narrative but a sequence of separate legal proceedings.
Key Takeaways for Researchers
The essential facts can be summarized simply.
First, Innovasis faced a major federal healthcare matter that ended in a $12 million settlement announced by the Justice Department in May 2024.
Second, that settlement concerned allegations of improper remuneration to physicians and was connected to a False Claims Act whistleblower action.
Third, Robert Richardson, identified by the DOJ as a former Innovasis regional sales director, received approximately $2.2 million from the recovery under the whistleblower provisions.
Fourth, Innovasis separately litigated against Michael English and Curiteva in federal court in Utah.
Fifth, the English litigation generated multiple procedural rulings, including a December 2023 dismissal and several 2024 discovery decisions.
Sixth, RSB Spine separately sued Innovasis over alleged patent infringement in 2024, and public case information indicates that proceeding was later closed.
Seventh, another Innovasis-related contract action was filed in June 2026 against Michael English and Ricardo Fontg, with Brent A. Felix joining Innovasis as a plaintiff.
These distinctions are essential for understanding what the phrase innovasis lawsuit actually means.
The Legal Record Going Forward
The Innovasis story remains a useful example of why legal research should be based on primary court records and government announcements rather than isolated headlines.
The $12 million settlement is a documented federal resolution. The allegations behind it should remain identified as allegations where appropriate.
The 2023–2024 litigation against English and Curiteva has its own procedural history and should not be merged with the federal healthcare case.
The RSB Spine patent matter likewise represents a separate dispute concerning intellectual property.
And the 2026 case creates another chapter in the company’s litigation history, with the publicly available docket confirming that the action was filed and amended but not establishing a final outcome.
For readers, journalists, researchers, healthcare professionals, and business observers, the central lesson is straightforward: the words “Innovasis lawsuit” describe a collection of legal events rather than one universally defined case.
Understanding the parties, dates, claims, and outcomes of each proceeding provides a much clearer picture of Innovasis’s legal history and prevents unrelated allegations or procedural developments from being presented as though they were part of one lawsuit.
